New clinical data found that combining two existing inflammatory bowel disease medications outperformed each drug used individually, especially in patients who had not responded adequately to monotherapy. Investigators presented outcomes showing improved remission rates when the therapies were administered together under monitored protocols.
Gastroenterologists said the results offer a pathway for refractory cases where single-agent biologics or immunomodulators fail to control flares. Combination regimens require careful oversight because stacked immunosuppression can elevate infection risk.
Patient groups welcomed evidence of additional options but emphasized affordability and insurance coverage remain barriers in many health systems. Trial participants were followed for symptom scores, endoscopic healing, and steroid-sparing effects across treatment cycles.
Manufacturers have not announced universal pricing changes, leaving physicians to navigate formulary restrictions case by case. Researchers plan subgroup analyses to determine which disease phenotypes benefit most from dual therapy.
The findings may influence treatment algorithms in specialty societies reviewing standard-of-care sequences for moderate-to-severe IBD.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.medicalnewstoday.com/news